Stocknear Logo Stocknear
/
Popular
  • KO Coca Cola Company Stock
  • TSLA Tesla Inc Stock
  • AMD Advanced Micro Devices Stock
  • SPY SPDR S&P 500 ETF Trust ETF
  • NVDA Nvidia Stock
    • Login

    AtriCure Inc.

    NASDAQ: ATRC · Real-Time Price · USD
    31.61
    -0.72 (-2.23%)
    At close: Jun 13, 2025, 3:59 PM
    31.62
    0.03%
    After-hours: Jun 13, 2025, 04:44 PM EDT
    -2.23%
    Bid 30
    Market Cap 1.56B
    Revenue (ttm) 480.08M
    Net Income (ttm) -38.18M
    EPS (ttm) -0.81
    PE Ratio (ttm) -39.02
    Forward PE -94.29
    Analyst Buy
    Ask 33.17
    Volume 263,584
    Avg. Volume (20D) 602,919
    Open 31.76
    Previous Close 32.33
    Day's Range 31.55 - 32.30
    52-Week Range 18.94 - 43.11
    Beta 1.60

    About ATRC

    undefined

    [Read more]
    Industry n/a
    Sector n/a
    IPO Date n/a
    Employees NaN
    Stock Exchange n/a
    Ticker Symbol ATRC
    Website n/a
    Full Company Profile

    Analyst Forecast

    According to 0 analyst ratings, the average rating for ATRC stock is "n/a." The 12-month stock price forecast is $n/a, which is a decrease of 0% from the latest price.

    Stock Forecasts

    Why Price Moved

    Why Price Moved is a one-sentence explanation of why a stock is moving higher or down. By removing noise and collecting signals from news, press releases and SEC filings, we can pinpoint the trigger for price movements.
    1 month ago
    -13.68%
    AtriCure shares are trading lower after the compan... Unlock content with Pro Subscription
    2 months ago
    -7.39%
    Atricutre shares are trading lower after Canaccord Genuity cut its price target on the stock from $66 to $52.
    news image

    3 weeks ago · businesswire.com

    AtriCure to Participate in the Goldman Sachs 46th Annual Global Healthcare Conference

    MASON, Ohio--(BUSINESS WIRE)--AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management, and post-o...

    news image

    1 month ago · zacks.com

    Does AtriCure (ATRC) Have the Potential to Rally 54.7% as Wall Street Analysts Expect?

    The consensus price target hints at a 54.7% upside potential for AtriCure (ATRC). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate...

    news image

    1 month ago · seekingalpha.com

    AtriCure, Inc. (ATRC) Q1 2025 Earnings Call Transcript

    AtriCure, Inc. (NASDAQ:ATRC ) Q1 2025 Earnings Conference Call April 29, 2025 4:30 PM ET Company Participants Marissa Bych - Investor Relations, Gilmartin Group Michael Carrel - President and Chief Ex...

    news image

    1 month ago · zacks.com

    AtriCure (ATRC) Q1 Earnings: Taking a Look at Key Metrics Versus Estimates

    The headline numbers for AtriCure (ATRC) give insight into how the company performed in the quarter ended March 2025, but it may be worthwhile to compare some of its key metrics to Wall Street estimat...

    news image

    1 month ago · zacks.com

    AtriCure (ATRC) Reports Q1 Loss, Tops Revenue Estimates

    AtriCure (ATRC) came out with a quarterly loss of $0.14 per share versus the Zacks Consensus Estimate of a loss of $0.25. This compares to loss of $0.25 per share a year ago.

    news image

    1 month ago · businesswire.com

    AtriCure Reports First Quarter 2025 Financial Results

    MASON, Ohio--(BUSINESS WIRE)--AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management and post-op...

    news image

    2 months ago · businesswire.com

    AtriCure to Announce First Quarter 2025 Financial Results

    MASON, Ohio--(BUSINESS WIRE)--AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management, and post-o...

    Add to Watchlist